Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: The past, the present, and the future

AIDS and Behavior

Volumn 10, Issue 3, 2006, Pages 249-251

  Bangsberg, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; CASI; Electronic medication monitor; HIV; Mediset; Pill box organizer; Resistance

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; NONHUMAN; NOTE; SELF REPORT; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; FORECASTING; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 33745266359     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-006-9121-7     Document Type: Note

References (22)

1. Artinian, N. T., Harden, J. K., Kronenberg, M. W., Vander Wal, J. S., Daher, E., & Stephens, Q. (2003). Pilot study of a Web-based compliance monitoring device for patients with congestive heart failure. Heart Lung, 52(4), 226-233.
2. Bangsberg, D. R., Acosta, E., Gupta, R., Guzman, D., Riley, E. D., & Harrigan, P. R. (2005). Differences in protease and non-nucleoside reverse transcriptase inhibitor adherence-resistance relationships are explained by virologic fitness. AIDS, 20(2), 223-231.
3. Bangsberg, D. R., Bronstone, A., Chesney, M. A., & Hecht, F. M. (2002). Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. Journal Acquired Immune Deficiency Syndrome, 31(Suppl. 3), S107-S111.
4. Bangsberg, D. R., Charlebois, E. D., Grant, R. M., Holodniy, M., Deeks, S. G., & Perry, S. (2003). High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS, 17(13), 1925-1932.
5. Bangsberg, D. R., Hecht, F., Clague, H., Charlebois, E., Ciccarone, D., & Chesney, M. (2001). Provider assessment of adherence to HIV antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 26(5), 435-442.
6. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolop, A. R., Holodniy, M., & Sheiner, L. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS, 14(4), 357-366.
7. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., & Zolopa, A. R. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS, 15(9), 1181-1183.
8. Bova, C. A., Fennie, K. P., Knafl, G. J., Dieckhaus, K. D., Watrous, E., & Williams, A. B. (2005). Use of electronic monitoring devices to measure antiretroviral adherence: Practical considerations. AIDS Behavior, 9(1), 103-110.
9. de Olalla, G., Knobel, H., Carmona, A., Guelar, A., Lopez-Colomes, J. L., & Cayla, J. A. (2002). Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal Acquired Immune Deficiency Syndrome, 30(1), 105-110.
10. Gross, R., Bilker, W. B., Friedman, H. M., Coyne, J. C., & Strom, B. L. (2002). Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS, 16(13), 1835-1837.
11. Gross, R., Zhang, Y., & Grossberg, R. (2005). Medication refill logistics and refill adherence in HIV. Pharmacoepidemiology and Drug Safety.
12. Hogg, R., Heath, K., Bangsberg, D. R., Yip, B., Press, N., & O'Shaughnessy, M. V. (2002). Intermittent use of Triple Combination Therapy is Predictive of Mortality at Baseline and after one year of follow-up AIDS. AIDS, 16, 1051-1058.
13. Jauhar, S. (2006). The demise of the physical exam. New England Journal of Medicine, 354(6), 548-551.
14. King, M. S., Brun, S. C., & Kempt, D. J. (2005). Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. Journal of Infectious Diseases, 191(12), 2046-2052.
15. Maggiolo, F., Ravasio, L., Ripamonti, D., Gregis, G., Quinzan, G., & Arici, C. (2005). Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clinical Infectious Diseases, 40(1), 158-163.
16. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115-1121.
17. Parienti, J., Massari, V., Descamps, D., Vabret, A., Bouvet, E., & Larouzé, B. (2004). Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine or Efavirenz-Based Antiretroviral Therapy. CID, 38, 1311-1316.
18. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., & Squier, C. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medcine, 133(1), 21-30.
19. Ruskin, P., Van der Wende, J., Clark, C., Fenton, J., Deveau, J., & Thapar, R. (2003). Feasibility of using the Med-eMonitor System in the treatment of Schizophrenia: A pilot study. Drug Information Journal, 37(3), 283-291.
20. Simoni, J., Kurth, A., Pearson, C., Pantalone, D., Merrill, J., & Frick, P. (2006). Self-reported measures of antiretroviral therapy adherence. Aids and Behavior.
21. Spacek, L. A., Shihab, H. M., Kamya, M. R., Mwesigire, D., Ronald, A., Mayanja, H., et al. (2006). Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clinical Infectious Diseases, 42(2), 252-259.
22. Weiser, S. D., Guzman, D., Riley, E. D., Clark, R., & Bangsberg, D. R. (2004). Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence. HIV Clinical Trials, 5(5), 278-287.